Can you drink alcohol on Wegovy?

No hard contraindication, but alcohol tolerance often drops sharply on GLP-1. Many patients also report reduced desire for alcohol — likely a secondary effect of GLP-1 on the brain reward system.

Does GLP-1 affect oral birth control?

Tirzepatide (Mounjaro, Zepbound) has documented reduced absorption of oral contraceptives during the first 4 weeks of each dose increase. Use backup contraception for ~4 weeks after starting + after each step-up. Semaglutide has no documented effect.

Can I take GLP-1 while pregnant?

No. All FDA-approved GLP-1s carry a pregnancy contraindication. Stop GLP-1 at least 2 months before planned conception due to its long half-life.

Is it safe to take GLP-1 long-term?

Liraglutide has 15+ years of post-marketing data (Victoza approved 2010). Semaglutide has 8+ years (Ozempic approved 2017). No new class-wide safety signals have emerged in extended follow-up. Chronic use is the FDA-approved indication for both T2D and obesity.

What happens if I miss a weekly GLP-1 dose?

If within 5 days: take the missed dose as soon as you remember, then resume the regular schedule. More than 5 days late: skip it and inject your next scheduled dose. Never double up.

Can GLP-1 cause thyroid cancer?

The boxed warning is based on rodent studies showing medullary thyroid carcinoma (MTC) in mice and rats. No human cases have been attributed to GLP-1 use despite 10+ years post-approval surveillance.

T2D: Symptoms, Risks & GLP-1 Treatment

glpverdict

Subscribe Sign in

Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content

GLP-1 evidence for type 2 diabetes

Editorial grades summarizing study quality and convergence. How we grade.

Claim	Grade	Basis
Semaglutide lowers A1C by 1.0-1.8 percentage points vs placebo Source: Lancet Diabetes & Endocrinology, 2018 (opens in a new tab) SUSTAIN-1 through SUSTAIN-7 RCTs (n~11,000 combined)	AStrong evidence	SUSTAIN-1 through SUSTAIN-7 RCTs (n~11,000 combined)
Semaglutide reduces 3-point MACE in T2D + established CV disease Source: NEJM, 2016 (opens in a new tab) SUSTAIN-6 (n=3,297), 26% relative MACE reduction	AStrong evidence	SUSTAIN-6 (n=3,297), 26% relative MACE reduction
Tirzepatide outperforms semaglutide on A1C reduction head-to-head Source: NEJM, 2021 (opens in a new tab) SURPASS-2 (n=1,879), tirzepatide superior at all 3 doses	AStrong evidence	SURPASS-2 (n=1,879), tirzepatide superior at all 3 doses
Semaglutide slows kidney function decline in T2D + CKD Source: NEJM, 2024 (opens in a new tab) FLOW trial (n=3,533), 24% slower eGFR decline	AStrong evidence	FLOW trial (n=3,533), 24% slower eGFR decline
GLP-1 therapy causes pancreatic cancer Decade-long pharmacovigilance data shows no causal link; mechanistic concern only	FNo evidence	Decade-long pharmacovigilance data shows no causal link; mechanistic concern only

Type 2 diabetes(T2D)

Overview

Symptoms

Risk factors

Treatment options

GLP-1 evidence for type 2 diabetes

Related GLP-1 medications

Mounjaro

Ozempic

Ozempic

Common questions readers ask

Sources